Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients
Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients
Recruiting · NCT07366658 · Registry updated 2026-06-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 | 2026-06-25 | NCT07366658 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 294 |
| Neukio Biotherapeutics (Shanghai) Co., Ltd. | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Hospital of CICAMS | Beijing | China | 1 |